CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 78 enrolled
Drug / intervention
Magrolimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02953782
NCT02953782Phase 2Completed
CompareCT.gov

A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer

Gilead Sciences·interventional·Posted Nov 3, 2016·Updated Mar 1, 2021

In Brief

A Phase 2 clinical trial evaluating Magrolimab and Cetuximab for Solid Tumor and Colorectal Cancer. Completed, enrolled 78 participants across 8 sites.

Detailed Summary

The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Colorectal Cancer
CountriesUnited States
CollaboratorsCalifornia Institute for Regenerative Medicine (CIRM)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 3, 2016
Enrollment StartNov 2, 2016
Primary CompletionFeb 10, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.7 years ago

Interventions

Magrolimabdrug

Administered intravenously

Cetuximabdrug

Administered intravenously